FDA Approves Additional Recommended Dose of Pembrolizumab in Adults

The FDA approved an additional recommended dose of 400 mg pembrolizumab (Keytruda) every 6 weeks across all adult indications.

Hope Rugo, MD, on the Accelerated Approval of Sacituzumab Govitecan-hziy

The breast cancer expert discussed the implications of this approval, as well as the data that led to the approval of sacituzumab govitecan-hziy.

Medicaid Not Associated with Improved Survival in Patients with SCLC

These findings suggest that there are significant outcome inequalities for patients with small cell lung cancer which are relevant to the policy debate on Medicaid expansion under the Affordable Care Act.